A Study of Standard Drugs for Mycobacterium Avium Complex

Sex: All

Ages: 18 Years – 100 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 10

Sponsor: Johns Hopkins University

Summary

To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Isolation of M. avium intracellulare complex from a respiratory specimen in the preceding 6 months * Fulfill American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) criteria for MAC lung disease * Intention by the treating clinician to treat for MAC lung disease. * Ability to produce a sputum sample of at least 10mL in a 16 hour period * Signed informed consent by the subject Exclusion Criteria: * Prior treatment for pulmonary MAC within the past 6 months * Pregnancy * HIV with a cluster of differentiation 4 (CD4) \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04287049). StuddyBuddy aggregates publicly available trial information.